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shown supervised exercise therapy (SET) to be more effective regarding walking distance and
quality of life than a ‘go home and walk’ advice (WA) for patients with intermittent claudica-
tion. The present study aims to assess the cost-effectiveness of SET versus WA.
Patients and methods: Data from the EXITPAD study, a 12-month randomised controlled trial in
304 patients with claudication, was used to study the proportion of costs to walking distance
and quality of life. Two different incremental cost-effectiveness ratios (ICERs) were calculated
for SET versus WA: costs per extra metre on the treadmill test, and costs per quality-adjusted
life year (QALY). QALYs were based on utilities derived from the EuroQoL-5 dimensions
(EQ-5D).
Results: Mean total costs were higher for SET than for WA (3407 versus 2304 Euros), mainly
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Intermittent claudication (IC) is defined as atherosclerotic
disease of the arteries of the legs, causing walking impair-
ment due to muscular pain. Although IC is not directly life
threatening, it implies that the patient has a very serious
vascular disease. Moreover, IC has been found to be associ-
atedwith a significantly lowered quality of life, which can be
improvedwith therapy.1 Exercise therapy is considered to be
the main conservative treatment for patients with IC.
However, compliance with unsupervised exercise therapy is
reported to be low.2 In the Exercise Therapy in Peripheral
Arterial Disease (EXITPAD) study, a multicentre randomised
trial, Nicolaı¨ et al.3 have shown that supervised exercise
therapy (SET) is more effective than an (unsupervised)
walking advice (WA) when it concerns walking distance,
score on the Walking Impairment Questionnaire (WIQ)4 and
Quality of Life as measured with the short form 36 health
survey (SF-36) questionnaire.5 Because supervision obviously
means an investment, in the present study, a cost-effec-
tiveness analysis is performed to answer the question
whether supervised exercise therapy is value for money
compared with a ‘go home and walk’ advice.
Materials and Methods
Patients and interventions
From the 11 participating outpatient vascular surgery clinics,
304 patients with peripheral arterial disease, stage II
according to Fontaine and eligible for conservative treat-
ment, were enrolled in the EXITPAD study. Inclusion criteria
were an ankle-brachial index (ABI) less than 0.9 and an
absolute claudication distance (ACD) below 500m. Exclusion
criteria included a prior supervised exercise therapy pro-
gramme for intermittent claudication, previous peripheral
vascular intervention, insufficient command of the Dutch
language, serious cardiopulmonary limitations (New York
Heart Association (NYHA) 3e4), previous lower-limb ampu-
tation, psychiatric instability and other serious co-morbidity
which may hinder physical training. Patients were rando-
mised to one of three possible interventions: WA, SET or SET
with feedback. Patients in the WA group received an oral
walking advice, together with a brochure. They were
instructed to complete three training sessions per day. In
each session, maximum pain level should be reached three
times. Patients in the SET groups were referred to a local
physical therapist. Themain goal of the physical therapywas
to increase thepatient’swalking distanceby interval training
up to maximal pain with short walking intervals, in combi-
nation with walking pattern improvement and enhancement
of endurance and strength. The frequency of therapy wastwo to three sessions of 30 min per week. During the treat-
ment year, this frequency could be adjusted depending on
the individual need of the patient.
In addition to physical therapy, patients in the SET with
feedback group received an accelerometer (Personal Activity
Meter (PAM), PAM B.V., Doorwerth, the Netherlands), which
assesses physical activity during daily routine. Patients were
instructed to wear the PAM during the whole treatment year,
and record the score on a daily basis. The physical therapist
used the PAM score for feedback on the patient’s walking
efforts outside the therapy setting. Of the 304 patients, 102
were randomised to the WA group, 109 to the SET group, and
93 to the SETwith feedback group. Follow-up was for 1 year.
Patients who did not perform a 12-month treadmill test were
treated in conformity with the clinical trial, which applied
a modified intention-to-treat method and did not include
those patients in the analysis. This left 83 patients in the WA
group for analysis, and 169 in the SET group (76 with and 93
without feedback). For a detailed overview of themethods of
the EXTIPAD trial, see Nicolaı¨ et al.3
Outcome measurements
In the economic evaluation, two outcome measurements
were considered. The first was the walking distance, or the
absolute claudication distance, in metres, on the treadmill
assessment at the end of the treatment year. The second
was the Quality of Life (QoL) as assessed with the EuroQoL-
5 dimensions (EQ-5D), which was filled out by the patients
at baseline and at the 3-, 6-, 9- and 12-month-assessments.
The EQ-5D instrument,6 a self-report measure, is
a descriptive system with five questions, each representing
one dimension of Health-related Quality of Life (HRQoL),
which are mobility, self-care, daily activities, pain/
discomfort and depression/anxiety. Each dimension can be
rated at three levels: no problems, some problems and
major problems, and together classify persons into 1 of 243
possible health states. Based on preferences elicited from
a general UK population,7 EQ-5D health states can be con-
verted into utility scores, ranging from 0.59 (worst
imaginable health state) to 1 (best imaginable health
state). A quality-adjusted life year (QALY) is calculated by
multiplying the utility score with the time that the patient
was experiencing that utility. When a patient was in the
best imaginable health state for 1 year that would lead to 1
QALY. With a utility score of 0.8 over 2 years, the number of
QALYs would be 1.6.
Costs
Theanalysis tooka societal perspective,which implies that all
relevant costs, inside and outside the health-care sector,
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gathered bymeans of a retrospective cost questionnaire with
a 3-month recall period, which took place at baseline and at
the 3-, 6-, 9- and 12-month assessments. For calculation of
cost-effectiveness, only costs after baselinewereconsidered.
The cost questionnaire contained items on general physician
(GP) contacts, outpatient visits, visits to the emergency room
(ER), hospital admissions, therapy sessions at the physical
therapist, contacts with the company doctor, home care and
informal care, prescribed and over-the-counter (OTC) medi-
cation, devices such as special shoes or a treadmill and lost
productivity because of absence from both paid and unpaid
work. Further, for all visits to health-care providers, patients
were asked to report theirmeans of transportation, to beable
to compute travel costs. Per type of health-care provider,
a mean travel distance was applied, based on the number of
available practices per square kilometre in the Netherlands.
Furthermore, for patients included in the Atrium MC in
Heerlen, which was a subsample of 123 patients, costs of
hospital procedures, related to both outpatient visits as well
as hospital admission, were collected from the hospital
databases. When possible, standard prices from the Dutch
manual for cost researchwere used.8 For hospital procedures,
prices from the financial department of the Atrium MC were
applied. Prices for medication were derived from the Dutch
Pharmacotherapeutic Compass.9 When necessary, prices
were converted to theprice level of 2008bymeans of national
price index figures.10 The costs of the PAM, which wereV 79,
werenot included in theanalysis. This costwouldonlyapply to
the patients who were in the SET plus feedback condition,
which ispartof the total SETgroup.As theclinical trial already
found that PAM did not add to the effectiveness of standard
SET, we decided to calculate the cost-effectiveness of SET
versus WA excluding the cost of PAM, as this, in our opinion,
best reflects the cost-effectiveness of supervised exercise
therapy.
Cost-effectiveness
The costs and outcomes were combined into two Incre-
mental Cost-Effectiveness Ratios (ICERs), which divide the
difference in costs between the two strategies by the
difference in effect between the strategies. An ICER can be
interpreted as the extra costs for the experimental inter-
vention that have to be invested to gain one extra unit of
effect. The first ICER is the cost per extra metre on the
treadmill test after 1 year, with the difference in effect
calculated as mean walking distance in the interventionTable 1 Mean (SD) EQ-5D utility scores per measurement and t
WA SET
T0 0.62 (0.23) 0.66 (0.20)
T3 0.68 (0.23) 0.69 (0.21)
T6 0.69 (0.19) 0.72 (0.17)
T9 0.68 (0.23) 0.73 (0.21)
T12 0.66 (0.26) 0.74 (0.20)
QALY 0.67 0.71group minus the mean walking distance in the control
group, and the second is the cost per QALY.
Data analysis
Missing items were imputed with the overall mean for the
respective variable. As cost data are generally highly
skewed, and not distributed normally, we used non-para-
metric bootstrap simulations performed in Microsoft Excel
with 1000 replications to estimate uncertainty intervals
around the ICERs.11,12 The uncertainty interval is repre-
sented by the 2.5th and 97.5th percentiles. When a differ-
ence has an uncertainty interval which does not include
zero, it is statistically significant. The results of ICER
bootstraps are presented in cost-effectiveness planes and
cost-effectiveness acceptability curves (CEACs).13 Cost-
effectiveness planes show differences in costs on the
vertical axis and differences in effect on the horizontal
axis. Bootstrapped cost-effectiveness pairs located in the
northwest quadrant indicate SET to be inferior to WA (more
costly and less effective than WA). Cost-effectiveness pairs
located in the southeast quadrant show SET to be dominant
over WA (more effective and less costly than WA). With
respect to the other two quadrants (higher costs for better
effectiveness and lower costs for lower effectiveness), the
preference for an intervention depends on the threshold
value, that is, what society is prepared to pay for an
effectiveness gain, or willing to accept as savings for
effectiveness loss. The CEAC represents the probability
that, given a certain threshold for the willingness to pay for
a QALY or for extra metre on the treadmill test, the inter-
vention is cost-effective. A CEAC is constructed by taking
a certain threshold (e.g., V 20 000 per QALY) and calcu-
lating the percentage of the 1000 bootstrapped ICERs that
are below that threshold, and therefore cost-effective,
given that threshold. By repeating this procedure for
various thresholds, a curve is generated, with threshold on
the x-axis and probability of the intervention being cost-
effective on the y-axis.Results
Walking distance
At baseline, both groups walked a median distance of
260 m, with comparable interquartile ranges (160e370 for
WA and 165e370 for SET). At the 12-month treadmill test,otal mean QALYs.
P-value (ManneWhitney)
0.51
0.50
0.40
0.03
0.03
Difference (bootstrapped 2.5the97.5th perc)
0.038 (0.0003e0.0796)
Table 2 Mean volumes (SD) and costs (SD), and mean difference in costs with bootstrapped 2.5th and 97.5th percentiles. Sign cant differences (where zero is not included in
the confidence interval between the 2.5th and 97.5th percentile) are shown in bold.
Cost category Unit price WA SET Difference (SETeWA)
Volume (SD) Cost (SD) Volume (SD) C t (SD) Cost (2.5the97.5th perc)
Exercise therapya V 24.67 per session 5.68 (10.33) V 148.87 (270) 59.62 (31.93) V 573.85 (844) V 1424.98 (1296e1561)
Hospital days V 387 per day 0.19 (0.75) V 74.09 (288) 0.24 (1.26) V 1.57 (487) V 17.49 (75.11e126.01)
Hospital procedures NA, various prices 55.82 (30.18) V 1458.53 (1512) 52.99 (39.31) V 249.83 (1235) V 208.71 (600e124)
Outpatient visitsa V 67 1.27 (2.04) V 88.12 (142) 1.67 (2.51) V 16.23 (174) V 28.11 (11.76e65.11)
GP contactsa At practice V 21.91 1.50 (2.61) V 31.37 (50.11) 1.75 (3.29) V 1.12 (84.97) V 9.75 (6.24e27.15)
At home V 43.81
Telephone V 10.95
GP night/ERa At practice V 21.91 0.11 (0.61) V 13.13 (58.45) 0.07 (0.26) V .60 (31.49) V 5.54 (19.29e6.96)
At home V 43.81
Telephone V 10.95
ER V 150.75
Company doctora V 70 0.02 (0.11) V 1.66 (8.44) 0.07 (0.71) V .24 (52.20) V 3.58 (2.03e12.38)
Home care/informal care V 36.98 (Home care) 15.47 (48.32) V 334.22 (1193) 12.62 (47.48) V 28.46 (797) V 105.76 (393e155)
V 9.00 (Inf care)
Medication/Out-of-pocket NA V 5.80 (24.41) V .47 (12.70) V 3.33 (9.44e1.74)
Unpaid productivity per hour 3.92 (12.66) V 35.26 (113.92) 7.67 (31.25) V 9.06 (281) V 33.80 (12.76e83.91)
Paid productivity per hour 0.37 (112.86) V 112.86 (652) 0.07 (0.65) V 2.07 (197) V 90.79 (252.38e18.24)
Total costs V 2304 (2228) V 407 (2071) V 1104 (528e1647)
a Costs do not match exactly with unit price  volume because travel costs (dependent on distance and means of transportation) e included.
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Figure 1 Incremental cost-effectiveness plane for cost per
QALY (SET versus WA), showing all 1000 bootstrapped cost-
effectiveness pairs. The cost-effectiveness plane consists of
four quadrants. Dots in the upper quadrants indicate higher
costs for SET, whereas dots in the lower quadrants represent
higher costs for WA. Dots to the right of the Y-axis indicate
better effects (more QALYs) for SET, and dots to the left of the
Y-axis mean better effects for WA. The northwest quadrant
contains cost-effectiveness pairs which are both more effec-
tive and less costly (i.e., dominant) for SET, the southeast
quadrant means dominancy for WA. As most of the boot-
strapped pairs are in the northeast quadrant, this means that
SET is more effective in terms of QALYs, but at a certain price.
Figure 2 Incremental cost-effectiveness plane for cost per
metre walking distance (SET versus WA). All cost-effectiveness
pairs are situated in the northeast quadrant, implying that SET
is more effective in terms of walking distance, but also more
expensive.
Cost-effectiveness of SET versus Walk Advice 101the patients in the SET groups scored significantly better on
walking distance than the patients in the WA group; the
median walking distance of the SET patients was 600 m
(interquartile range 435e1040) as opposed to 400 m
(230e590) for the WA-patients (p-value < 0.001).3
Quality of Life
Table 1 shows mean EQ-5D utility scores for all assessments.
At baseline, the difference in utility scores is not statisti-
cally significant. At 9 and 12 months, the SET group has
significantly higher scores than the WA group. This also
translates to the mean QALYs, which are 0.67 and 0.71 for
WA and SET, respectively. The difference between the
groups is 0.038, with a bootstrapped 2.5th percentile of
0.0003 and a 97.5th percentile of 0.0796, indicating
a significant gain in quality of life, as zero is not included in
the uncertainty interval.
Costs
Volumes and costs of cost categories are shown in Table 2.
Total costs for the SET group are statistically significantly
higher, as expected. The difference is caused mainly by the
costs of exercise therapy. The other cost categories are
more or less comparable between the groups, except for
the productivity costs for paid work, which seem to be
higher for the WA group, and the costs of home care and
informal care, which seem to be higher for the SET group.
However, the bootstrapped 95% uncertainty intervals for
these categories, which consist of the 2.5th and 97.5th
percentile, indicate that these differences are not statis-
tically significant.
Cost-effectiveness
The ICER for cost per extra metre on the 12-month tread-
mill test is V 4.08. For cost per QALY, the ICER is V 28693.
The incremental cost-effectiveness plane of the 1000
bootstrap replications for cost per QALY is shown in Fig. 1.
Most of the cost-effectiveness pairs are located in the
upper-right quadrant, where SET is more costly than WA,
but also more effective. A minority of replications is situ-
ated in the upper-left quadrant, where SET is more costly
and less effective than WA. The fact that the replications
are divided over the upper two quadrants indicates there is
some uncertainty concerning the effectiveness of SET
regarding QALYs. However, considering that only two 24
replications (less than 2.5%) are in the upper-left quadrant,
this uncertainty is very minor. The fact that there are no
replications in the lower quadrants indicates that there is
no uncertainty regarding costs.
Fig. 2 shows the incremental cost-effectiveness plane
for cost per metre on the 12-month treadmill test. All 1000
replications are in the upper-right quadrant, indicating that
there is no uncertainty whatsoever; SET is more costly and
more effective than WA when it concerns walking distance.
Because, for both outcome measures, SET is more costly
and more effective, the probability of SET being cost-
effective depends on the amount society is willing to pay to
gain a QALY or an extra metre. Cost-effectivenessacceptability curves show that probability in relation to this
so-called willingness to pay, or cost-effectiveness
threshold. For cost per QALY (Fig. 3), when for instance the
cost-effectiveness threshold is V 40 000, the probability of
SET being cost-effective compared with WA is almost 64%.
For cost per metre (Fig. 4), a very high probability (85%) is
already reached at a cost-effectiveness threshold of V 6.
Discussion
The cost-effectiveness analysis of the EXITPAD study
showed that SET was more costly and more effective than
WA, for both QALYs and walking distance. The probability of
SET being cost-effective therefore depends on the cost-
effectiveness threshold that is applied. For cost per metre,
this is a very difficult issue, as there is no previous infor-
mation, and therefore no frame of reference, on cost-
Figure 3 Cost-effectiveness acceptability curve for cost per
QALY. The curve indicates the probability that SET is cost-
effective, given the societal willingness to pay (threshold
value) for one QALY gained.
102 A.D.I. van Asselt et al.effectiveness concerning this outcome parameter. The
point where the probability of SET being cost-effective
exceeds 50%, therefore, where the probability that SET is
more cost-effective than WA is higher than the probability
that WA is more cost-effective than SET, is reached at about
V 4.15 per extra metre.
For costperQALY,many formaland informal thresholdsare
being used. There is no clear consensus in the literature about
what is considered a reasonable amount to pay for a QALY
gained. For instance, Laupacis suggested a range between
V 12 000 and V 60 000 for the Ontario guidelines.14 Although
the stated threshold of the British National Institute for Clin-
ical Excellence (NICE) threshold is £ 30 000 (about V 34 000),
their revealed threshold, that is, the threshold that can be
derived on the basis of the interventions that are included in
the insurance package, is £ 55 000 (almost V 63 000), nearly
twice as high. In the Netherlands, recently, the suggestion has
been made to include burden of disease into the cost-effec-
tiveness threshold.15 With the burden of disease varying from
0 to 1, with a higher number indicating a higher burden, the
thresholdwouldbeV 80000perQALY for a highlyburdensome
disease (score1),while treatment ofdiseaseswithaburdenof
less than 0.10 should not be in the insurance package at all;
therefore, there the threshold is zero. For claudication, theFigure 4 Cost-effectiveness acceptability curve for cost per
metre. The curve indicates the probability that SET is cost-
effective, given the societal willingness to pay for one extra
metre on the treadmill test.burden of disease is not known; however, for heart- and
peripheral arterial disease, it is 0.55 and for hip arthrosis, it is
0.42. As claudication falls into the same range of complaints,
one could assume that the burden of disease for claudication
is 0.50. The threshold for a disease burden of 0.5 as advised by
the Dutch Council for Public Health and Health Care is about
V 40 000, which corresponds with a probability of SET being
cost-effective of 64%.
The incremental cost-effectiveness as studied in the
EXITPAD study concerns SET versus WA. Another frequently
performed intervention in claudication patients is a percu-
taneous vascular intervention (PVI) for revascularisation.
Spronk et al.16 compared the cost-effectiveness of a PVI
versus hospital-based exercise therapy and concluded that,
as therewas not a significant difference in effectiveness, but
revascularisation is much more costly, exercise was the
preferred therapy. However, two studies investigating the
effectiveness of a PVI versus SETon walking distance showed
conflicting results.17,18 It is clear that, of the three options,
PVI is the most costly and WA is the most economical. More-
over, exercise therapy is a safe option compared with a PVI,
which, being an invasive procedure, carries the risk of
complications.19
Amajor strength of the present studywas that it collected
patient-level cost data for all relevant cost categories. For
the devices and medication, however, these cost data might
have been less reliable than for the other categories as the
frequency and length of use ofmedication was not recorded,
and for the devices as well as for the OTC drugs, patients
reported such an enormous variety of products (from vitamin
pills to Nordic walking sticks and health resorts) that it was
difficult to assign a realistic price to all items. Moreover, it is
questionable whether all patients interpreted the question
on the out-of-pocket costs in the same way. However, as can
be read from Table 2, the per-patient cost for this category is
very modest. Nevertheless, an additional analysis was per-
formed, excluding this specific cost category, leading to
results that were very comparable with the results of the
main analysis (i.e., V 2298 and V 3405 for WA and SET,
respectively). Hence, even if these cost items were unreli-
able, this could not impact the results and conclusions.
Summarising, for cost per extra metre on the treadmill,
with great certainty (85%) SET is cost-effective at V 6 per
metre. There is, however, no frame of reference for the
willingness to pay for lengthening the maximum walking
distance. For cost per QALY, assumed that V 40 000 is an
acceptable price to pay for a QALY; SET has a higher
probability than WA to be cost-effective. In conclusion, the
present economic evaluation shows that SET is likely a cost-
effective therapeutic option for patients with claudication.
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